Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued
Reference number: GID-TA11004
As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Pembrolizumab with enzalutamide within its marketing authorisation for treating metastatic hormone-relapsed prostate cancer.
Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in early August 2023 when we will write to you about how you can get involved.